Clinical Features And Prognosis Correlation Of C-kit Mutation In Acute Myeloid Leukemia Patients With T(8;21)chromosomal Translocations

Objective:(1).Objective to investigate the prognostic factors of acute myeloid leukemia patients with t(8;21).(2).To analyze the clinical characteristics and prognosis of c-kit(C-kitproto)mutations and t(8;21)AML patients,and to analyze the clinical characteristics and prognosis of other poor prognosis genes.Methods:A total of 67 patients with a complete t(8;21)AML patients were enrolled in this study.From January 2011 to January 2016,patients were admitted to the Department of Hematology,Second Affiliated Hospital of Shanxi Medical University,Information and living conditions.(1)67 cases of t(8;21)AML patients were divided into c-kit mutation group and negative group,using statistical methods to compare the two groups of patients with general information,clinical features.(2)Considering the presence of poor prognosis in c-kit mutant group,it may affect the results.On this basis,the negative components were further treated with poor prognosis and poor prognosis,respectively,compared with c-kit mutant group.Results:(1)Compared with the negative group,the difference of platelet count between the two groups was statistically significant(P<0.05).The positive rate of CD56 and cMPOwas statistically significant(P<0.05).There was no significant difference in complete remission rate,recurrence rate,survival time and outcome between the two groups(P>0.05).(2)Compared with the poor prognosis group,the c-kit mutation group and the poor prognosis group had high white blood cell count,the difference was statistically significant(P<0.05),c-kit mutation and poor prognosis between the white blood cell count was not statistically significant(P>0.05).The difference of platelet count between C-kit mutation group and good prognosis group was statistically significant(P<0.05)There was no significant difference in platelet count between c-kit mutation group and poor prognosis group,poor prognosis group and poor prognosis group(P>0.05).Compared with the other two groups,the positive rate of CD56 in c-kit was high and the positive rate of cMPO was low(P<0.05).(3)The survival time of c-kit mutation group and poor prognosis group was shorter than that of c-kit group(P<0.05),c-kit mutation group and prognosis There was no significant difference in survival time between the two groups(P>0.05).Poor prognosis group and the other two groups,high mortality,was statistically significant(P<0.05),no statistically significant difference in mortality between the c-kit mutation group and a good prognosis group(P>0.05).The recurrence rate was significantly higher in the poor group(55.6% vs 28.5% vs 25%),but there was no significant difference between the three groups.There was no significant difference in complete remission rate and recurrence time between the three groups(P>0.05).(4)The survival curves of the c-kit mutation group and the poor prognosis group were compared under the c-kit negative group.The prognosis of the c-kit mutation group and the poor prognosis group was better than that of the poor group,With other mutations in patients with poor prognosis worse prognosis.Conclusion:(1).C-kit mutation in t(8;21)positive AML patients with a incidence of 20.9%,withc-kit mutation of t(8;21)positive AML patients with high white blood cell count,low platelet count,the total survival time The positive rate of CD56 and cMPO were correlated with c-kit mutation,which could be used as the basis for the stratified treatment of t(8;21)AML patients.(2).Other poor prognosis mutations(FLT3,EVI,P53,etc.)in t(8;21)AML have a low incidence but have a greater impact on the prognosis of such patients,and the presence of mutations means worse prognosis.In-depth studies of these genes are necessary.